A PIPELINE BUILT TO MEET PATIENTS’ NEEDS.
Our global infrastructure of ongoing trials and studies is thriving. See our work to help find new treatments for serious diseases.
FILED
© 2024 Corcept Therapeutics, Incorporated
Hypercortisolism (Cushing Syndrome)
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
Endogenous Cushing syndrome (GRACE)
Relacorilant
PHASE III
Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)
Relacorilant
PHASE III
Extension study to evaluate long term safety
Relacorilant
PHASE III
Prevalence and treatment of hypercortisolism in patients with type 2 diabetes (CATALYST)
Korlym
PHASE IV
Prevalence of endogenous hypercortisolism in patients with resistant hypertension (MOMENTUM)
Oncology
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
Platinum-resistant ovarian cancer (ROSELLA)
Relacorilant + Abraxane (nab-paclitaxel)
PHASE III
Prostate cancer
Relacorilant + Xtandi (enzalutamide)1
PHASE II
Neurology
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
ALS (DAZALS)
Dazucorilant
PHASE II
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS / NON-ALCOHOLIC STEATOHEPATITIS
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
MASH/NASH
Miricorilant
PHASE II
Additional Areas of Research
MASH: metabolic dysfunction-associated steatohepatitis. NASH: non-alcoholic steatohepatitis. ALS: amyotrophic lateral sclerosis.
1 Investigator-sponsored trial, University of Chicago